

Supplemental digital content 2. Most frequently reported unsolicited adverse events following primary and booster vaccination (Total vaccinated cohort)

	<6S	<6NS	7-11S	7-11NS	12-23S	12-23NS
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Most frequent unsolicited AEs after primary vaccination						
Malaria	10 (20%)	7 (14%)	9 (18%)	13 (26%)	10 (20%)	10 (20%)
Bronchitis	9 (18%)	10 (20%)	3 (6%)	8 (16%)	1 (2%)	4 (8%)
Gastroenteritis	6 (12%)	5 (10%)	3 (6%)	9 (18%)	1 (2%)	6 (12%)
Most frequent unsolicited AEs after booster vaccination						
Malaria	-	8 (16%)	8 (16%)	4 (8%)		
Diarrhea	1 (2%)	2 (4%)	3 (6%)	1 (2%)		
Enteritis	-	2 (4%)	-	3 (6%)		

Footnote: <6S, infants with SCD enrolled at 8–11 weeks of age, primed with 3 doses and boosted with PHiD-CV + DTPw-HBV/Hib + OPV vaccines at 2, 3, 4 and 9–10 months of age; <6NS, infants without SCD enrolled at 8–11 weeks of age, primed with 3 doses and boosted with PHiD-CV + DTPw-HBV/Hib + OPV vaccines at 2, 3, 4 and 9–10 months of age; 7-11S, children with SCD enrolled at 7–11 months of age, primed with 2 doses and boosted with PHiD-CV; 7-11NS, children without SCD enrolled at 7–11 months of age, primed with 2 doses and boosted with PHiD-CV; 12-23S, children with SCD enrolled at 12–23 months of age, vaccinated with 2 doses of PHiD-CV; 12-23NS, children without SCD enrolled at 12–23 months of age, vaccinated with 2 doses of PHiD-CV; n (%), number (percentage) of children for which the unsolicited AE was reported in the 31-day post-vaccination period; AE, adverse event; SCD, sickle cell disease. We are reporting the 3 most frequently reported unsolicited AEs (classified as higher total number of children reporting the unsolicited AE).